Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2015
  • Online publication date: April 2015

Chapter 16 - Uterine leiomyomas: epidemiology, diagnosis, and management

from Section 2 - General gynecology

References

1. Shwartz, SM. Epidemiology of uterine leiomyomata. Clin Obstet Gynecol 2001;44:316–326.
2. ButtramVC, ReiterRC. Uterine leiomyomata: etiology, symptomatology and management. Fertil Steril 1981;36:433–445.
3. LumsdenMA, WallaceEM. Clinical presentation of uterine fibroids. Bailliere's Clin Obstet Gynaecol 1998;12:177–195.
4. CramerSF, PatelA. The frequency of uterine leiomyomas. Am J Clin Pathol 1990;94:435–438.
5. MarshallLM, SpeigelmanD, BarbieriR, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol 1997;90:967–973.
6. RossRK, PikeM, VesseyMP, et al. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. BMJ 1986;293:359–362.
7. LaughlinSK, SchorederJC, BairdDD. New directions in the epidemiology of uterine fibroids. Semin Reprod Med 2010;28:204–217.
8. FaersteinE, SzkloM, RosensheinNB. Risk factors for uterine leiomyoma: a practice-based case–control study. I. African-American heritage, reproductive history, body size, and smoking. Am J Epidemiol 2001;153:1–10.
9. BairdDD, DunsonDB, HillMC, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003;188:100–107.
10. GrossKL, PanhuysenCI, KleinmanMS, et al. Involvement of fumarate hydratase in nonsyndromic uterine leiomyomas: genetic linkage analysis and FISH studies. Genes Chromos Cancer 2004;41:183–190.
11. HodgeJC, CuencoK, HuyckKL, et al. Uterine leiomyomata and decreased height: a common HMGA2 predisposition allele. Hum Genet 2009;125:257–263.
12. Al-HendyA, SalamaSA. Ethnic distribution of estrogen receptor-alpha polymorphism is associated with a higher prevalence of uterine leiomyomas in black Americans. Fertil Steril 2006;86:686–693.
13. Al-HendyA, SalamaSA. Catechol-O-methyltransferase polymorphism is associated with increased uterine leiomyoma risk in different ethnic groups. J Soc Gynecol Invest 2006;13:136–144.
14. LuoX, CheginiN. The expression and potential regulatory function of microRNAs in the pathogenesis of leiomyoma. Semin Reprod Med 2008;26:500–514.
15. TaranFA, BrownHL, StewartEA. Racial diversity in uterine leiomyoma clinical studies. Fertil Steril 2010;94:1500–1503.
16. WalkerCL. Role of hormonal and reproductive factors in the etiology and treatment of uterine leiomyoma. Rec Prog Horm Res 2002;57:277–294.
17. MarshallLM, Spiegelman, GoldmanMB, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 1998;70:432–439.
18. SamadiAR, LeeNC, FlandersWD, et al. Risk factors for self reported uterine fibroids: a case control study. Am J Pub Health 1996;86:858–862.
19. RomieuI, WalkerAM, JickS. Determinants of uterine fibroids. Post Market Surveil 1991;5:119–133.
20. LumbiganonP, RugpaoS, Phandhu-FungS, et al. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicenter case–control study. Br J Obstet Gynaecol 1995;103:909–914.
21. WiseLA, PalmerJR, HarlowBL, et al. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol 2004;159:113–123.
22. ChenCR, BuckGM, CoureyNG, et al. Risk factors for uterine fibroids among women undergoing tubal sterilization. Am J Epidemiol 2001;153:20–26.
23. ParazziniF, NegriE, La VecchiaC, et al. Reproductive factors and risk of uterine fibroids. Epidemiology 1996;7:440–442.
24. ReinMS, BarbieriRL, Friedman, AJ. Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol 1995;172:14–18.
25. SenerAB, SeckinNC, OzmenS, et al. The effects of hormone replacement therapy on uterine fibroids in postmenopausal women. Fertil Steril 1996;65:354–357.
26. YangCH, LeeJN, HsuSC, et al. Effect of hormone replacement therapy on uterine fibroids in postmenopausal women: a 3-year study. Maturitas 2002;43:35–39.
27. FedeleL, BianchiS, RaffaelliR, et al. A randomized study of the effects of tibolone and transdermal estrogen replacement therapy in postmenopausal women with uterine myomas. Eur J Obstet Gynecol Reprod Biol 2000;88:91–94.
28. de AloysioD, AltieriP, PenacchioniP, et al. Bleeding patterns in recent postmenopausal outpatients with uterine myomas: comparison between two regimens of HRT. Maturitas 1998;29:261–264.
29. ReedSD, Cushing-HaugenKL, Daling, JR, et al. Postmenopausal estrogen and progestogen therapy and the risk of uterine leiomyomas. Menopause 2004;11:214–222.
30. MarshallLM, SpiegelmanD, MansonJE, et al. Risk of uterine leiomyomata among premenopausal women in relation to body size and cigarette smoking. Epidemiology 1998;9:511–517.
31. ParazziniF, LaVecchiaC, NegriE, et al. Epidemiologic characteristics of women with uterine fibroids: case–control study. Obstet Gynecol 1988;72:853–857.
32. TerryKL, De ViroI, HankinsonSE, et al. Anthropometric characteristics and risk of uterine leiomyoma. Epidemiology 2007;18:758–763.
33. BairdDD, DunsonDB, HillMC, CousinsD, SchectmanJM. Association of physical activity with development of uterine leiomyoma. Am J Epidemiol 2007;165:157–163.
34. ParazziniF, NegriE, La VecchiaC, et al. Uterine myomas and smoking. Results from an Italian study. J Reprod Med 1996;41:316–320.
35. FlakeGP, AndersenJ, DixonD. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 2003;111:1037–1054.
36. WiseLA, PalmerJR, HarlowBL, et al. Risk of uterine leiomyomata in relation to tobacco, alcohol and caffeine consumption in the Black Women's Health Study. Hum Reprod 2004;19:1746–1754.
37. TownsendDE, SparkesRS, BaludaMC, et al. Unicellular histogenesis of uterine leiomyomas as determined by electrophoresis of glucose-6-phosphate dehydrogenase. Am J Obstet Gynecol 1970;107:1168–1173.
38. MashalRD, FejzoMLS, FriedmanAJ, et al. Analysis of androgen receptor DNA reveals the independent clonal origins of uterine leiomyomata and the secondary nature of cytogenetic aberrations in the development of leiomyomata. Genes Chromos Cancer 1994;11:1–6.
39. HashimotoK, AzumaC, KamiuraS, et al. Clonal determination of uterine leiomyomas by analyzing differential inactivation of the X-chromosome-linked phosphoglycerokinase gene. Gynecol Obstet Invest 1995;40:204–208.
40. GrossKL, MortonCC. Genetics and the development of fibroids. Clin Obstet Gynecol 2001;44:335–349.
41. GattasGJ, QuadeBJ, NowakRA, et al. HMGIC expression in human adult and fetal tissues and in uterine leiomyomata. Genes Chromos Cancer 1999;25:316–322.
42. PedeutourF, QuadeBJ, WeremowiczS, et al. Localization and expression of the human estrogen receptor beta gene in uterine leiomyomata. Genes Chromos Cancer 1998;23:361–366.
43. KazmierczakB, Dal CinP, WanschuraS, et al. HMGIY is the target of 6p21.3 rearrangements in various benign mesenchymal tumors. Genes Chromos Cancer 1998;23:279–285.
44. TalliniG, Dal CinP, RhodenKJ, et al. Expression of HMGI-C and HMGI(Y) in ordinary lipoma and atypical lipomatous tumors: immunohistochemical reactivity correlates with karyotypic alterations. Am J Pathol 1997;151:37–43.
45. XiaoS, LuxM, ReevesR, et al. HMGI(Y) activation by chromosome 6p21 rearrangements in multilineage mesenchymal cells from pulmonary hamartoma. Am J Pathol 1997;150:901–910.
46. Dal CinP, WanschuraS, ChristiaensMR, et al. Hamartoma of the breast with involvement of 6p21 and rearrangement of HMGIY. Genes Chromos Cancer 1997;20:90–92.
47. Dal CinP, van den BergheH, et al. Involvement of 6p in an endometrial polyp. Cancer Genet Cytogenet 1991;51:279–280.
48. SornbergerKS, WeremowiczS, WilliamsAJ, et al. Expression of HMGIY in three uterine leiomyomata with complex rearrangements of chromosome 6. Cancer Gene Cytogenet 1999;114:9–16.
49. LigonAH, MortonCC. Genetics of uterine leiomyomata. Genes Chromos Cancer 2000;28:235–245.
50. VanniR, Van RoyN, LeccaU, et al. Uterine leiomyoma cytogenetics. III. Interphase cytogenetic analysis of karyotypically normal uterine leiomyoma excludes possibility of undetected trisomy 12. Cancer Genet Cytogenet 1992;62:40–42.
51. LigonAH, MortonCC. Leiomyomata: heritability and cytogenetic studies. Genes Chromos Cancer 2000;28:235–245.
52. TreloarSA, MartinNG, DennersteinL, et al. Pathways to hysterectomy: insights from longitudinal twin research. Am J Obstet Gynecol 1992;167:82–88.
53. LuotoR, KaprioJ, RutanenEM, et al. Heritability and risk factors of uterine fibroids: the Finnish Twin Cohort study. Maturitas 2000;37:15–26.
54. WinklerVDH, HoffmannW. Regarding the question of inheritance of uterine myoma. D Med Wochenschr 1938;68:235–257.
55. KurbanovaM, KorolevaAG, SergeevAS. Genetic-epidemiological analysis of uterine myoma: estimate of risk to relatives. Genetika 1989;25:1896–1898.
56. VikhlyaevaEM, KhodzhaevaZS, FantschenkoND. Familial predisposition to uterine leiomyomas. Int J Gynecol Obstet 1995;51:127–131.
57. SchwartzSM, VoigtL, TickmanE, et al. Familial aggregation of uterine leiomyomata. Am J Epidemiol 2000;151:S10.
58. SadanO, van IddekingeB, van GelderenCJ, et al. Oestrogen and progesterone receptor concentrations in leiomyoma and normal myometrium. Ann Clin Biochem 1987;24:263–267.
59. BenassayagC, LeroyMJ, RigourdV, et al. Estrogen receptors (ERalpha/ERbeta) in normal and pathological growth of the human myometrium: pregnancy and leiomyoma. Am J Physiol 1999;276:E1112–1118.
60. FolkerdEJ, NewtonCJ, DavidsonK, et al. Aromatase activity in uterine leiomyomata. J Steroid Biochem 1984;20:1195–1200.
61. SumitaniH, ShozuM, SegawaT, et al. In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism. Endocrinology 2000;141:3852–3861.
62. YammamtoT, TakamoriK, OkadaH. Estrogen biosynthesis in leiomyoma and myometrium of the uterus. Horm Metab Res 1984;16:678–679.
63. SpellacyWN, Le MaireWJ, BuhiWC, et al. Plasma growth hormone and estradiol levels in women with uterine myomas. Obstet Gynecol 1972;40:829–834.
64. MaheuxR, Lemay-TurcotL, LemayA. Daily follicle-stimulating hormone, luteinizing hormone, estradiol, and progesterone in ten women harboring uterine leiomyomas. Fertil Steril 1986;46:205–208.
65. DawoodMY, Khan-DawoodFS. Plasma insulin-like growth factor-I, CA-125, estrogen, and progesterone in women with leiomyomas. Fertil Steril 1994;61:617–621.
66. LiehrJG, RicciMJ, JefcoateCR, et al. 4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. Proc Natl Acad Sci USA 1995;92:9220–9224.
67. BrandonDD, BetheaCL, StrawnEY, et al. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol 1993;169:78–85.
68. VivilleB, Charnock-JonesDS, SharkeyAM, et al. Distribution of the A and B forms of the progesterone receptor messenger ribonucleic acid and protein in uterine leiomyomata and adjacent myometrium. Hum Reprod 1997;12:815–822.
69. OtubuJA, ButtramVC, BeschNF, et al. Unconjugated steroids in leiomyomas and tumor-bearing myometrium. Am J Obstet Gynecol 1982;143:130–133.
70. TiltmanAJ. The effect of progestins on the mitotic activity of uterine fibromyomas. Int J Gynecol Path 1985;4:89–96.
71. KawaguchiD, FujiiS, KonishiI, et al. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol 1989;160:637–641.
72. KawaguchiK, FujiiS, KonishiI, et al. Ultrastructural study of cultured smooth muscle cells from uterine leiomyoma and myometrium under the influence of sex steroids. Gynecol Oncol 1985;21:32–41.
73. MaruoT, MatsuoH, SamotoT, et al. Effects of progesterone on uterine leiomyoma growth and apoptosis. Steroids 2000;65:585–592.
74. HofmannGE, RaoCV, BarrowsGH, et al. Binding sites for epidermal growth factor in human uterine tissues and leiomyoma. J Clin Endocrinol Metab 1984;58:880–884.
75. NelsonKG, TakahashiT, BossertNL, et al. Epidermal growth factor replaces estrogen in the stimulation of female genital-tract growth and differentiation. Proc Natl Acad Sci USA 1991;88:21–25.
76. YehJ, ReinM, NowakR. Presence of messenger ribonucleic acid for epidermal growth factor (EGF) and EGF receptor demonstrable in monolayer cell cultures of myometrial and leiomyoma. Fertil Steril 1991;56:997–1000.
77. RossiMJ, CheginiN, MastersonBJ. Presence of epidermal growth factor, platelet-derived growth factor (PDGF), and their receptors in human myometrial tissue and smooth muscle cells: their action in smooth muscle cells in vitro. Endocrinology 1992;130:1716–1727.
78. LyonsRM, MosesHL. Transforming growth factors and the regulation of cell proliferation. Eur J Biochem 1990;187:467–473.
79. MatsuoH, MaruoT, SamotoT. Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab 1997;82:293–299.
80. ValentiMT, AzzarelloG, VinanteO, et al. Differentiation, proliferation and apoptosis levels in human leiomyoma and leiomyosarcoma. J Cancer Res Clin Oncol 1998;124:93–105.
81. VuK, GreenspanDL, WuT-C, et al. Cellular proliferation, estrogen receptor, progesterone receptor, and BCL-2 expression in GnRH agonist-treated uterine leiomyomas. Hum Pathol 1998;29:359–363.
82. StewartEA. Uterine fibroids. Lancet 2001;357:293–298.
83. StovallDW. Clinical symptomatology of uterine leiomyomas. Clin Obstet Gynecol 2001;44:364–371.
84. BettocchiS, CeciO, VicinoM, et al. Diagnostic inadequacy of dilation and curettage. Fertil Steril 2001;75:803–805.
85. PronG, BennettJ, CommonA, et al. The Ontario Uterine Fibroid Embolization Trial. Part 2. Uterine fibroid reduction and symptom relief after uterine artery embolization for fibroids. Fertil Steril 2003;79:120–127.
86. RyboG, LemanJ, TibbinR. Epidemiology of menstrual blood loss. In BairdDT, MichieaP (eds.) Mechanisms of Menstrual Bleeding. New York: Raven, 1985; pp. 181–193.
87. Farrer-BrownG, BobbeilbyJOW, TarbitNH. Venous changes in the endometrium of myomatous uteri. Obstet Gynecol 1971;38:743–751.
88. YamaguchiM, MoriN. Prostaglandin production by human myometrium, uterine cervix and leiomyoma. ProsaglandinLeukot Med 1987;29:107–112.
89. AndersonJ. Factors in fibroid growth. Bailliere's Clin Obstet Gynecol 1998;12:233–238.
90. VercelliniP, VendolaN, RagniG, et al. Abnormal uterine bleeding associated with iron deficiency anemia. Etiology and role of hysteroscopy. J Reprod Med 1993;38:502–504.
91. LippmanSA, WarnerM, SamuelsS, et al. Uterine fibroids and gynecologic pain symptoms in a population-based study. Fertil Steril 2003;80:1488–1494.
92. KjerulffKH, LangenbergP, SeidmanJD, et al. Uterine leiomyomas: racial differences in severity, symptoms, and age at diagnosis. J Reprod Med 1994;41:483–490.
93. HaraT, TsuchidaM, TakaiK, et al. Ureteral obstruction in a transplanted kidney secondary to a subserous myoma uteri. Transplant 2003;75:1915–1916.
94. ReiterRC, WagnerPL, GamboneJC. Routine hysterectomy for large asymptomatic uterine leiomyomata: a reappraisal. Obstet Gynecol 1992;79:481–484.
95. ChaparalaRPC, FawoleAS, AmbroseNS, et al. Large bowel obstruction due to a benign uterine leiomyoma. Gut 2004;53:386.
96. BajekalN, LiTC. Fibroids, infertility and pregnancy wastage. Hum Reprod Update 2000;6:614–620.
97. PrittsEA. Fibroids and infertility: a systematic review of the evidence. Obstet Gynecol Surv 2001;56:483–491.
98. PrittsEA, ParkerWH, OliveDL. Fibroids and infertility: An updated systematic review of the evidence. Fertil Steril 2009;91:1215–1223.
99. UbaldiF, TournayeH, CamusM, et al. Fertility after hysteroscopic myomectomy. Hum Reprod Update 1995;1:81–90.
100. BullettiC, De ZieglerD, PolliV, et al. The role of leiomyomas in infertility. J Am Assoc Gynecol Laparosc 1999;6:441–445.
101. DonnezJ, JadoulP. What are the implications of myomas on fertility? A need for a debate? Hum Reprod 2002;17:1424–1430.
102. HartR, KhalafY, YeongCT, et al. A prospective controlled study of the effect of intramural uterine fibroids on the outcome of assisted conception. Hum Reprod 2001;16:2411–2417.
103. OliveiraFG, AbdelmassihVG, DiamondMP, et al. Impact of subserosal and intramural uterine fibroids that do not distort the endometrial cavity on the outcome of in vitro fertilization-intracytoplasmic sperm injection. Fertil Steril 2004;81:582–587.
104. CheckJH, ChoeJK, LeeG, et al. The effect on IVF outcome of small intramural fibroids not compressing the uterine cavity as determined by a prospective matched control study. Hum Reprod 2002;17:1244–1248.
105. NgEHY, HoPC. Doppler ultrasound examination of uterine arteries on the day of oocyte retrieval in patients with uterine fibroids undergoing IVF. Hum Reprod 2002;17:765–770.
106. SunkaraSK, KhairyM, El-ToukhyT, KhalafY, CoomarasamyA. The effect of intramural fibroids without uterine cavity involvement on the outcome of IVF treatment: a systematic review and meta-analysis. Hum Reprod 2010;25:418–429.
107. SurreyES. Impact of intramural leiomyomata on in-vitro fertilization-embryo transfer cycle outcome. Curr Opin Obstet Gynecol 2003;15:239–242.
108. MuramD, GilliesonM, WaltersJH. Myomas of the uterus in pregnancy: ultrasonographic follow-up. Am J Obstet Gynecol 1980;138:16–19.
109. MyersER, BarberM, CouchmanGM, et al. Management of Uterine Fibroids [Evidence Report/Technology Assessment]. Rockville, MD: Agency for Healthcare Research and Quality, 2001.
110. BensonCB, ChowJS, Chang-LeeW, et al. Outcome of pregnancies in women with uterine leiomyomas identified by sonography in the first trimester. J Clin Ultrasound 2001;29:261–264.
111. LiTC, MortimerR, CookeID. Myomectomy: a retrospective study to examine reproductive performance before and after surgery. Hum Reprod 1999;14:1735–1740.
112. CoronadoGD, MarshallLM, SchwartzSM. Complications in pregnancy, labor, and delivery with uterine leiomyomas: a population-based study. Obstet Gynecol 2000;95:764–769.
113. SalvadorE, BienstockJ, BlakemoreKJ, et al. Leiomyomata uteri, genetic amniocentesis, and the risk of second-trimester spontaneous abortion. Am J Obstet Gynecol 2002;186:913–915.
114. LanouetteJM, DiamondMP. Pregnancy in women with myoma uteri. Infert Reprod Med Clin North Am 1996;7:19–32.
115. KatzV, DottersDJ, DroegemuellerW. Complications of uterine leiomyomas in pregnancy. Obstet Gynecol 1989;73:593–596.
116. CantuariaGHC, AngioliR, FrostL, et al. Comparison of bimanual examination with ultrasound examination before hysterectomy for uterine leiomyoma. Obstet Gynecol 1998;92:109–112.
117. GoldbergJM, FalconeT, AttaranM. Sonohysterographic evaluation of uterine abnormalities noted on hysterosalpingography. Hum Reprod 1997;12:2151–2153.
118. PittawayDE, WinfieldAC, MaxsonW, et al. Prevention of acute pelvic inflammatory disease after hysterosalpingography: efficacy of doxycycline prophylaxis. Am J Obstet Gynecol 1983;147:623–626.
119. HurleyV. Imaging techniques for fibroid detection. Bailliere's Clin Obstet Gynecol 1998;12:213–224.
120. KarasickS, Lev-ToaffAS, ToaffME. Imaging of uterine leiomyomas. Am J Roentgenol 1992;158:799–805.
121. MayerDP, ShipilovV. Ultrasonography and magnetic resonance imaging of uterine fibroids. Obstet Gynecol Clin North Am 1995;22:667–725.
122. FedeleL, BianchiS, DortaM, et al. Transvaginal sonography versus hysteroscopy in the diagnosis of uterine submucous myomas. Obstet Gynecol 1991;77:745–748.
123. DueholmM, LundorfE, HansenES, et al. Accuracy of magnetic resonance imaging and transvaginal ultrasonography in the diagnosis, mapping, and measurement of uterine myomas. Am J Obstet Gynecol 2002;186:409–415.
124. de VriesLD, DijkhuizenFP, MolBW, et al. Comparison of transvaginal sonography, saline infusion sonography, and hysteroscopy in premenopausal women with abnormal uterine bleeding. J Clin Ultrasound 2000;28:217–223.
125. SylvestreC, ChildTJ, TulandiT, et al. A prospective study to evaluate the efficacy of two- and three-dimensional sonohysterography in women with intrauterine lesions. Fertil Steril 2003;79:1222–1225.
126. BrunnerM, ObrucaA, BauerP, et al. Clinical application of volume estimation based on three dimensional ultrasonography. Ultrasound Obstet Gynecol 1995;6:359–361.
127. JurkovicD. Three-dimensional ultrasound in gynecology: a critical evaluation. Ultrasound Obstet Gynecol 2002;19:109–117.
128. PretoriusDH, BeckerE, Lev-ToaffAS. Impact of sonohysterography on the management of women with uterine myomas. Ultrasound Obstet Gynecol 2001;18(Suppl):2.
129. HricakH, TscholakoffD, HeinrichsL, et al. Uterine leiomyomas: correlation of MR, histopathological findings, and symptoms. Radiology 1986;158;385–391.
130. AscherSM, JhaRC, ReinholdC. Benign myometrial conditions: leiomyomas and adenomyosis. Top Magn Reson Imaging 2003;14:281–304.
131. LefebvreG, VilosGA, AllaireC, et al. SOGC Clinical practice guidelines: The management of uterine leiomyomas. J Obstet Gynaecol Can 2003;25:396–405.
132. SchwartzLB, DiamondMP, SchwartzPE. Leiomyosarcomas: clinical presentation. Am J Obstet Gynecol 1993;168:180–183.
133. MeyerWR, MayerAR, DiamondMP, et al. Unsuspected leiomyosarcoma: treatment with a gonadotropin-releasing hormone analogue. Obstet Gynecol 1990;75:529–532.
134. CarrBR, MarshburnPB, WeatherallPT, et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 1993;76:1217–1223.
135. SivinI, SternJ. Health during prolonged use of levonorgestrel 20mcg/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research. Fertil Steril 1994, 61:70–77.
136. PekonenF, NymanT, LahteenmakiP, et al. Intrauterine progestin induces continuous insulin-like growth factor- binding protein-1 production in the human endometrium. J Clin Endocrinol Metab 1992;75:660–664.
137. LaurenB, ZapataLB, WhitemanMK, TepperNK, et al. Intrauterine device use among women with uterine fibroids: a systematic review. Contraception 2010;82:41–55.
138. MagalhaesJ, Mendes AldrighiJ, Rodriguesde Lima G. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas. Contraception 2007;75:193–198.
139. MakarainenL, YlikorkalaO. Primary and myoma-associated menorrhagia: role of prostaglandins and effects of ibuprofen. Br J Obstet Gynaecol 1986;93:974–978.
140. YlikorkalaO, PekonenF. Naproxen reduces idiopathic but not fibromyoma-induced menorrhagia. Obstet Gynecol 1986;68:10–12.
141. FriedmanAJ, BarbieriRL, BenacerrafBR, et al. Treatment of leiomyomata with intranasal or subcutaneous leuprolide, a gonadotropin-releasing hormone agonist. Fertil Steril 1987;48:560–564.
142. FriedmanAJ, HoffmanDI, ComiteF, et al. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. Obstet Gynecol 1991;77:720–725.
143. ChavezNF, StewartEA. Medical treatment of uterine fibroids. Clin Obstet Gynecol 2001;44:372–384.
144. ShawRW. Gonadotropin hormone-releasing hormone analogue treatment of fibroids. Bailliere's Clin Obstet Gynecol 1998;12:245–268.
145. LemayA, MaheuxR. GnRH agonists in the management of uterine leiomyoma. Infert Reprod Med Clin North Am 1996;7:33–55.
146. FarquaharC, ArrollB, EkeromaA, et al. An evidence based guideline for the management of uterine fibroids. Aust N Z J Obstet Gynaecol 2001;41:125–140.
147. DonnezJ, SchrursB, GillerotS, et al. Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography. Fertil Steril 1989;51:947–950.
148. WatanabeY, NakamuraG. Effects of two different doses of leuprolide acetate depot on uterine cavity area in patients with uterine leiomyomata. Fertil Steril 1995;63:487–490.
149. FriedmanAJ, DalyM, Juneau-NorcrossMJ, et al. Predictors of uterine volume reduction in women with myomas treated with a gonadotropin-releasing hormone agonist. Fertil Steril 1992;8:413–415.
150. GutmannJN, ThorntonKL, DiamondMP, et al. Evaluation of leuprolide acetate treatment on histopathology of uterine myomata. Fertil Steril 1994;61:622–626.
151. FriedmanAJ, Harrison-AtlasD, BarbieriRL, et al. A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata. Fertil Steril 1989;51:251–256.
152. DubuissonJB, FauconnierA, FourchotteV, et al. Laparoscopic myomectomy: predicting the risk of conversion to an open procedure. Human Reprod 2001;16:1726–1731.
153. MattaWHM, StabileI, ShawRW, et al. Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin releasing hormone agonist buserelin. Fertil Steril 1988;46:1083–1085.
154. ShawRW. Blood flow changes in the uterus induced by treatment with GnRH analogues. Hum Reprod 1996;11:27–32.
155. SerraGB, PanettaV, ColosimoM, et al. Efficacy of leuprorelin acetate depot in symptomatic fibromatous uteri: the Italian multicenter trial. Clin Ther 1992;14:57–73.
156. WestCP, LumsdenMA, BairdJT. Goserelin in the treatment of fibroids. Br J Obstet Gynecol 1992;99(Suppl):27–30.
157. HehenkampWJ, VolkersNA, BirnieE, ReekersJA, AnkumWM. Symptomatic uterine fibroids: treatment with uterine artery embolization or hysterectomy: results from the randomized clinical Embolization versus Hysterectomy (EMMY) Trial. Radiology 2008;246:823–832.
158. EdwardsRD, MossJG, LumsdenMA, et al. Committee of the Randomized Trial of Embolization versus Surgical Treatment for Fibroids. Uterine-artery embolization versus surgery for symptomatic uterine fibroids. N Engl J Med 2007;356:360–370.
159. FriedmanAJ, DalyM, Juneau-NorcrossM, et al. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin “add-back” regimens for women with leiomyomata uteri. J Clin Endocrinol Metab 1993;76:1439–1445.
160. FriedmanAJ. Treatment of leiomyomata uteri with short-term leuprolide followed by leuprolide plus estrogen-progestin hormone replacement therapy for 2 years: a pilot study. Fertil Steril 1989;51:526–528.
161. MurphyAA. RU 486 in the treatment of leiomyomata uteri. Infert Reprod Med Clin North Am 1996;7:57–68.
162. DeMannoD, ElgerW, GargR, et al. Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids 2003;68:1019–1032.
163. ChwaliszK, LarsenL, Mattia-GoldbergC, et al. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril 2007;87:1399–1412.
164. MaruoT, OharaN, MatsuoH, et al. Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas. Contraception 2007;75:S99–103.
165. UekiM, OkamatoY, TsurunagaT, et al. Endocrinological and histological changes after treatment of uterine leiomyomas with danazol or buserelin. J Obstet Gynecol 1995;21:1–7.
166. De LeoV, MorganteG, LanzettaD, et al. Danazol administration after gonadotropin-releasing hormone analogue reduces rebound of uterine myomas. Hum Reprod 1997;12:357–360.
167. TakebayashiT, FujinoY, UmesakiN, et al. Danazol suspension injected into the uterine cervix of patients with adenomyomas and myoma. Gynecol Obstet Ivest 1995;39:207–211.
168. CoutinhoEM, GoncalvesMT. Long-term treatment of leiomyomas with gestrinone. Fertil Steril 1989;51:939–946.
169. MitwallyMF, CasperRF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 2001;75:305–309.
170. ParsanezhadME, AzmoonM, AlborziS, et al. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril 2010;93:192–198.
171. Eldar-GevaT, HealyDL. Other medical management of uterine fibroids. Baillieres Clin Obstet Gynaecol 1998;12:269–288.
172. JirecekS, LeeA, PavoI, et al. Raloxifene prevents the growth of uterine leiomyomas in premenopausal women. Fertil Steril 2004;81:132–136.
173. WuT, ChenXY, XieL, YangJ. Selective estrogen receptor modulators (SERMs) for uterine leiomyomas. Cochrane Database Syst Rev 2007;(4):1–22.
174. YuL, AhnagCT, CaoXM. The clinical observation of warm Needle (Ex-CA1) for uterine fibroids. J Clin Acupuncture Moxibustion 2005;21:45.
175. LiuJP, YangH, XiaY, CardiniF. Herbal preparations for uterine fibroids. Cochrane Database Syst Rev 2013;(4):CD005292.
176. RavinaJH, HerbreteauD, Ciraru-VigneronN, et al. Arterial occlusion to treat uterine myomata. Lancet 1995;346:671–672.
177. NickolicB, SpiesJB, LundstenMJ, et al. Patient radiation dose associated with uterine artery embolization. Radiology 2000;214:121–125.
178. WalkerWJ, PelageJP, SuttonC. Fibroid embolization. Clin Radiol 2002;57:325–331.
179. TropeanoG, DiStasiC, AmorosoA, et al. Incidence and risk factors for clinical failure of uterine leiomyoma embolization. Obstet Gynecol 2012;120:269–276.
180. GuptaJK, SinhaAS, LumsdenMA, HickeyM. Uterine artery embolization for symptomatic uterine fibroids. Cochrane Database Syst Rev 2012;(5):CD005073.
181. GoldbergJ, PereiraL, BerghellaV. Pregnancy after uterine artery embolization. Obstet Gynecol 2002;100:869–872.
182. ChenYJ, WangPH, YuanCC, et al. Pregnancy following treatment of symptomatic myomas with laparoscopic bipolar coagulation of uterine vessels. Hum Reprod 2003;18:1077–1081.
183. HomerH, SaridoganE. Uterine artery embolization for fibroids is associated with an increased risk of miscarriage. Fertil Steril 2010;94:324–930.
184. Worthington-KirschR, SpiesJB, MyersER, for the Fibroid Investigators. The Fibroid Registry for outcomes data (FIBROID) for uterine embolization: short term outcomes. Obstet Gynecol 2005;106:52–59.
185. VashishtA, StuddJ, CareyA, et al. Fatal septicaemia after fibroid embolization. Lancet 1999;354:307–308.
186. PelageJP, Le DrefO, SoyerP, et al. Fibroid-related menorrhagia: treatment with superselective embolization of the uterine arteries and mid term follow-up. Radiology 2000;215:428–431.
187. ChrismanHB, SakerMB, RyuR, et al. The impact of uterine fibroid embolization on resumption of menses and ovarian function. J Vasc Interv Radiol 2000;11:699–703.
188. Czeyda-PommersheimF, MageeST, CooperC, HahnWY, SpiesJB. Venous thromboembolism after uterine fibroid embolization. Cardiovasc Interv Radiol 2003;14:1147–1153.
189. HeinigJ, NeffA, CirkelU, et al. Recurrent leiomyomatosis peritonealis disseminata after hysterectomy and bilateral salpingo-oophorectomy during combined hormone replacement therapy. Eur J Obstet Gynecol Reprod Biol 2003;111:216–218.
190. CarlsonKJ, MillerBA, FowlerFJ. The Maine Women's Health Study: I. Outcomes of hysterectomy. Obstet Gynecol 1994;83:556–565.
191. DwyerN, HuttonJ, StirratGM. Randomised controlled trial comparing endometrial resection with abdominal hysterectomy for the surgical treatment of menorrhagia. Br J Obstet Gynaecol 1993;100:237–243.
192. ManyondaI, SinthamoneyaE, BelliAM. Controversies and challenges in the modern management of uterine fibroids. BJOG 2004;111:95–102.
193. PintoI, ChimenoP, RomoA, et al. Uterine fibroids: uterine artery embolization versus abdominal hysterectomy for treatment: a prospective, randomized, and controlled clinical trial. Radiology 2003;226:425–431.
194. HwangJL, SeowKM, TsaiYL, et al. Comparative study of vaginal, laparoscopically assisted vaginal and abdominal hysterectomies for uterine myoma larger than 6 cm in diameter or uterus weighing at least 450 g: a prospective randomized study. Acta Obstet Gynecol Scand 2002;81:1132–1138.
195. RibeiroSC, RibeiroRM, SantosNC, et al. A randomized study of total abdominal, vaginal and laparoscopic hysterectomy. Int J Gynecol Obstet 2003;83:37–43.
196. LearmanLA, SummittRL Jr., VarnerRE, et al. A randomized comparison of total or supracervical hysterectomy: surgical complications and clinical outcomes. Obstet Gynecol 2003;102:453–462.
197. VollenhovenBJ, LawrenceAS, HealyDL. Uterine fibroids: a clinical review. Br Obstet Gynaecol 1990;97:285.
198. WallachEE. Myomectomy. In ThompsonJD, RockJA (eds.) Telinde's Operative Gynecology. Philadelphia, PA: Lippincott-Raven, 1992, pp. 647–660.
199. LaMorteAL, LalwaniS, DiamondMP. Morbidity associated with abdominal myomectomy. Obstet Gynecol 1993;82:897.
200. IversonRE, ChelmowD, StrohbehnK, et al. Relative morbidity of abdominal hysterectomy and myomectomy for management of uterine leiomyomas. Obstet Gynecol 1996;88:415–419.
201. RosettiA, SizziO, SoronnaL, et al. Long-term results of laparoscopic myomectomy: recurrence rate in comparison with abdominal myomectomy. Hum Reprod 2001;16:770–774.
202. FauconnierA, ChapronC, Babaki-Fard, et al. Recurrence of leiomyomata after myomectomy. Hum Reprod Update 2000;6:595–602.
203. StewartEA, FaurEA, WiseLA, et al. Predictors of subsequent surgery for uterine leiomyomata after abdominal myomectomy. Obstet Gynecol 2002;99:426–432.
204. NisolleM, SmetsM, GillerotS, et al. Laparoscopic myolysis with the Nd:YAg laser. J Gynecol Surg 1993;9:95–99.
205. PhillipsDR, NathonsonHG, MilimSJ, et al. Experience with laparoscopic leiomyoma coagulation and concomitant operative hysteroscopy. J Am Assoc Gynecol Laparosc 1997;4:425–433.
206. VilosG, DalyL, TseB. Pregnancy outcome after laparoscopic myolysis. J Am Assoc Gynecol Laparosc 1998;5:289–292.
207. GlasserMH, ZimmermanJD. The hydrothermablator system for management of menorrhagia in women with submucous myomas: 12- to 20-month follow-up. J Am Assoc Gynecol Laparosc 2003;10:521–527.
208. LeeBB. Radiofrequency ablation of uterine leiomyomata: a new minimally invasive hysterectomy alternative. Obstet Gynecol 2002;99:9S.
209. ChudnoffSG, BermanJM, LevineDJ, et al. Outpatient procedure for the treatment and relief of symptomatic uterine myomas. Obstet Gynecol 2013;121:1075–1082.
210. MyersER, BarberMD, Gustilo-AshbyT, et al. Management of uterine leiomyomata: what do we really know?Obstet Gynecol 2002;100:8–17.